

## Interested in participating in a clinical research trial?

Scan QR code below to submit a form.



## Currently Enrolling Studies

### Amyloidosis

- **Eidos-AG10-501**- A phase 3 Randomized, Multicenter, Double-Blind, Placebo Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial). [NCT06563895](https://clinicaltrials.gov/ct2/show/study/NCT06563895)

### Amyotrophic Lateral Sclerosis (ALS)

- **PRECISION MED- Protocol 4800** – A single or multiple visit protocol for collection of DNA/RNA/SERUM/PLASMA/CSF in Amyotrophic Lateral Sclerosis and related disorders.

### Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

- **CIDP- 80202135CDP3001** – Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). [NCT05327114](https://clinicaltrials.gov/ct2/show/study/NCT05327114)
- **CIDP- ARGX-113-2406** - A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy Who Transition from Treatment with Intravenous Immunoglobulin to Efgartigimod PH20 SC. [NCT06637072](https://clinicaltrials.gov/ct2/show/study/NCT06637072)

### Idiopathic Inflammatory Myopathy (IIM)

- **ALKIVIA- ARGX-113-2007** – A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older with Active Idiopathic Inflammatory Myopathy. [NCT05523167](https://clinicaltrials.gov/ct2/show/study/NCT05523167)

### **Multifocal Motor Neuropathy (MMN)**

- **EMPASSION- ARGX-117-2302-** A Phase 3, Randomized, Double-Blinded, Double-Dummy Study evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults with Multifocal Motor Neuropathy. [NCT06742190](https://clinicaltrials.gov/ct2/show/study/NCT06742190)

### **Myasthenia Gravis (MG)**

- **NIMBLE - R3918-MG-2018** – Efficacy and Safety Of Pozelimab And Cemdisiran Combination Therapy In Patients With Symptomatic Generalized Myasthenia Gravis. [NCT05070858](https://clinicaltrials.gov/ct2/show/study/NCT05070858)
- **ADAPT SERON- ARGX-113-2308-** A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis. [NCT06298552](https://clinicaltrials.gov/ct2/show/study/NCT06298552)
- **ADAPT OCULUS- ARGX-113-2315 -** A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants with Ocular Myasthenia Gravis. [NCT06558279](https://clinicaltrials.gov/ct2/show/study/NCT06558279)

### **Postural orthostatic tachycardia syndrome (POTS)**

- **RECOVER-AUTONOMIC-** A Platform Protocol for Evaluation of Interventions for Autonomic Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). [NCT06305780](https://clinicaltrials.gov/ct2/show/study/NCT06305780)

### **Inclusion Body Myositis (IBM)**

- **IBM- R3918-OT-2383-** Efficacy and safety of Pozelimab and Cemdisiran combination therapy in patients with sporadic inclusion body myositis-Investigator Initiative Study. [NCT06479863](https://clinicaltrials.gov/ct2/show/study/NCT06479863)

### **Charcot-Marie-Tooth disorder (CMT Type 1 and Type 2)**

- **SYNAPSE-CMT- NMD670-02-0003-**A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 Over 21 Days in Ambulatory Adult Patients with Type 1 and Type 2 Charcot-Marie-Tooth Disease. [NCT06482437](https://clinicaltrials.gov/ct2/show/study/NCT06482437)